Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Docetaxel and Prednisone in HRPC
NCT00110214Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2005
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Apr 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00110214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110214.